GPR40 agonist 6 (Compound 7a) is a potent and selective agonist of free fatty acid receptor 1 ( FFAR1 or GPR40 ) with an EC 50 of 0.058 μM against GPR40 [1].

GPR40 agonist 6 (Compound 7a) exhibits a highly favorable ADME (Absorption, Distribution, Metabolism, and Excretion) profile, characterized by negligible inhibition of key cytochrome P450 isoforms (1A2, 2C9, 2C19, 2D6, and 3A4) at a concentration of 5 μM. Additionally, this compound demonstrates a 98.6% binding affinity to human plasma proteins and an aqueous solubility of 404 μM in PBS (pH 7.4). Its microsomal stability in mice, with a half-life of 434 minutes, and Caco-2 permeability rate of 15.2 x 10^-6 cm/s, further underscore its promising pharmacokinetic properties. These values, derived from averages of multiple experiments, highlight the compound's potential effectiveness and safety profile.